Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522417 · ClinicalTrials.gov registry record · Phase 2
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
A Phase 2 study, sponsored by Medicure.
- Completed
- Registry status
- Phase 2
- Development phase
- 535
- Enrollment target
NCT01522417 is a Phase 2 study that has completed, run by Medicure. The registered enrollment target is 535 participants.
The verdict
NCT01522417, a Phase 2 study, has completed, sponsored by Medicure.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 535 participants
- Enrollment target
Study Summary
The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocardial infarction, urgent target vessel revascularization or in-hospital major bleeding within 48 hours following PCI or hospital discharge, whichever comes first.
Interventions
- DRUG Eptifibatide
- DRUG Short Tirofiban
- DRUG Long Tirofiban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2012-04 |
| Est. Completion | 2019-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01522417
The ClinicalTrials.gov registry entry for NCT01522417 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicure, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Eptifibatide is the first listed.
NCT01522417 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01522417 about?
NCT01522417 is a clinical study titled "Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention". The purpose this study is to assess whether a tirofiban regimen of a high-dose bolus plus a shortened infusion duration compared to label-dosing eptifibatide in patients undergoing percutaneous coronary intervention (PCI) is associated with a non-inferior composite rate of death, PCI-related myocard...
What is the current status of trial NCT01522417?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 535 participants. The study started on 2012-04. Estimated completion is 2019-03.
What interventions are being tested in trial NCT01522417?
The interventions under investigation include: Eptifibatide (DRUG), Short Tirofiban (DRUG), Long Tirofiban (DRUG).
Who is sponsoring clinical trial NCT01522417?
This trial is sponsored by Medicure, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.